Patents by Inventor Henry J. George

Henry J. George has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of producing human-like glycosylation pattern using cells deficient in glutamine synthase, CMP-N-acetylneuraminic acid hydroxylase and/or glycoprotein alpha-1,3-galactosyltransferase
    Patent number: 9062338
    Abstract: The present invention provides non-human mammalian cell lines that are deficient in CMP-Neu5Ac hydroxylase (Cmah) and/or glycoprotein alpha-1,3-galactosyltransferase (Ggta1). Also provided are methods for using the cells disclosed herein for producing recombinant proteins with human-like patterns of glycosylation.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: June 23, 2015
    Assignee: SIGMA-ALDRICH CO. LLC
    Inventors: Nan Lin, Henry J. George, Joaquina Mascarenhas, Trevor N. Collingwood, Kevin J. Kayser, Katherine Achtien
  • CELLS DEFICIENT IN CMP-N-ACETYLNEURAMINIC ACID HYDROXYLASE AND/OR GLYCOPROTEIN ALPHA-1,3-GALACTOSYLTRANSFERASE
    Publication number: 20150152463
    Abstract: The present invention provides non-human mammalian cell lines that are deficient in CMP-Neu5Ac hydroxylase (Cmah) and/or glycoprotein alpha-1,3-galactosyltransferase (Ggta1). Also provided are methods for using the cells disclosed herein for producing recombinant proteins with human-like patterns of glycosylation.
    Type: Application
    Filed: January 30, 2015
    Publication date: June 4, 2015
    Applicant: SIGMA-ALDRICH CO. LLC
    Inventors: Nan Lin, Henry J. George, Joaquina Mascarenhas, Trevor N. Collingwood, Kevin J. Kayser, Katherine Achtien
  • Cells deficient in CMP-N-acetylneuraminic acid hydroxylase and/or glycoprotein alpha-1,3-galactosyltransferase
    Patent number: 8980583
    Abstract: The present invention provides non-human mammalian cell lines that are deficient in CMP-Neu5Ac hydroxylase (Cmah) and/or glycoprotein alpha-1,3-galactosyltransferase (Ggta1). Also provided are methods for using the cells disclosed herein for producing recombinant proteins with human-like patterns of glycosylation.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: March 17, 2015
    Assignee: Sigma-Aldrich Co. LLC
    Inventors: Nan Lin, Henry J. George, Joaquina Mascarenhas, Trevor N. Collingwood, Kevin J. Kayser, Katherine Achtien
  • CELLS DEFICIENT IN CMP-N-ACETYLNEURAMINIC ACID HYDROXYLASE AND/OR GLYCOPROTEIN ALPHA-1,3-GALACTOSYLTRANSFERASE
    Publication number: 20130004992
    Abstract: The present invention provides non-human mammalian cell lines that are deficient in CMP-Neu5Ac hydroxylase (Cmah) and/or glycoprotein alpha-1,3-galactosyltransferase (Ggta1). Also provided are methods for using the cells disclosed herein for producing recombinant proteins with human-like patterns of glycosylation.
    Type: Application
    Filed: June 29, 2012
    Publication date: January 3, 2013
    Applicant: SIGMA-ALDRICH CO. LLC
    Inventors: Nan Lin, Henry J. George, Joaquina Mascarenhas, Trevor N. Collingwood, Kevin J. Kayser, Katherine Achtien
  • Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
    Patent number: 6623981
    Abstract: This invention relates to the detection of patients at risk for developing integrin antagonist/agonist mediated disease states. This invention relates to assays useful for the detection in a patient bodily fluid sample of drug-dependent antibodies which bind to integrins, or intergrin-associated proteins or complexes thereof in the presence of an integrin antagonist/agonist. This invention also relates to assays useful for the detection in a patient bodily fluid sample of drug-dependent antibodies (DDABS) that bind to integrins, including the platelet glycoprotein IIb/IIIa (GPIIb/IIIa), in the presence of a integrin agonist and/or antagonist. This invention also relates to procedures for identifying integrin antagonists/agonists that are less prone to elicit integrin antagonist/agonist mediated disease states. This invention also relates to procedures which increase the recovery of integrin-directed antibodies in body fluids, resulting in an increased sensitivity and specificity of DDAB detection assays.
    Type: Grant
    Filed: January 26, 1999
    Date of Patent: September 23, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey T. Billheimer, Dietmar A. Seiffert, Leah A. Breth, Timothy C. Burn, Ira B. Dicker, Henry J. George, Gregory F. Hollis, Jeannine M. Hollis, Jennifer E. Kochie, Karyn T. O'Neil
  • DETECTION OF PATIENTS AT RISK FOR DEVELOPING INTEGRIN ANTAGONIST/ AGONIST MEDIATED DISEASE STATES
    Publication number: 20020081624
    Abstract: This invention relates to the detection of patients at risk for developing integrin antagonist/agonist mediated disease states. This invention relates to assays useful for the detection in a patient bodily fluid sample of drug-dependent antibodies which bind to integrins, or intergrin-associated proteins or complexes thereof in the presence of an integrin antagonist/agonist. This invention also relates to assays useful for the detection in a patient bodily fluid sample of drug-dependent antibodies (DDABS) that bind to integrins, including the platelet glycoprotein IIb/IIIa (GPIIb/IIIa), in the presence of a integrin agonist and/or antagonist. This invention also relates to procedures for identifying integrin antagonists/agonists that are less prone to elicit integrin antagonist/agonist mediated disease states.
    Type: Application
    Filed: January 26, 1999
    Publication date: June 27, 2002
    Inventors: JEFFREY T. BILLHEIMER, DIETMAR A. SEIFFERT, LEAH A. BRETH, TIMOTHY BURN, IRA B. DICKER, HENRY J. GEORGE, JEANNINE M. HOLLIS, GREGORY F. HOLLIS, JENNIFER E. KOCHIE, KARYN T. O'NEIL
  • Co-aggregate purification of proteins
    Patent number: 4673641
    Abstract: Methods are provided for stabilization and purification of proteins produced in host cell systems. The methods provide for significant stabilization of any unfused non-bacterial protein that is produced in the same host cell that is producing an aggregate-forming fusion protein or any aggregate-forming protein.
    Type: Grant
    Filed: January 25, 1984
    Date of Patent: June 16, 1987
    Assignee: Molecular Genetics Research and Development Limited Partnership
    Inventors: Henry J. George, Richard A. Krzyzek, Lynn W. Enquist, Roger J. Watson